Placebo-controlled trial of atenolol in treatment of pregnancy-associated hypertension.
Atenolol was compared with placebo in a randomised and double-blind prospective study of 120 women with mild to moderate pregnancy-associated hypertension who were also initially managed conventionally by bed rest. Atenolol given once daily significantly reduced blood-pressure, prevented proteinuria, and reduced the number of hospital admissions. Loss of blood-pressure control leading to withdrawal from the study was commoner among the placebo group, whose babies had a high morbidity. Respiratory distress syndrome occurred only in the placebo group. Intrauterine growth retardation, neonatal hypoglycaemia, and hyperbilirubinaemia occurred with the same frequency in the two groups. Neonatal bradycardia was more common after atenolol but the systolic blood-pressure of the babies was the same in both groups. There was no difference between the groups in maternal symptoms which could have been attributed to beta-blocker therapy. Thus atenolol is more effective than conventional obstetric management in this form of hypertension and does not adversely affect mother or baby.
D000328:Adult; D001262:Atenolol / Q000494:pharmacology / Q000627:therapeutic use*; D001510:Bed Rest; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000628:therapy; D007231:Infant, Newborn; D008431:Maternal-Fetal Exchange; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000188:drug therapy* / Q000628:therapy; D011263:Pregnancy Trimester, Third; D011412:Propanolamines / Q000627:therapeutic use*; D011507:Proteinuria / Q000517:prevention & control; D011897:Random Allocation; D012127:Respiratory Distress Syndrome, Newborn / Q000517:prevention & control
D011412:Propanolamines; D001262:Atenolol